Cory Cramer is a Contributor at Seeking Alpha. He specializes in finance and trading, focusing on investment strategies, stocks and bonds, wealth management, and asset management. His insights and analyses have been featured in various financial discussions, contributing to a deeper understanding of the investment landscape.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Cory Cramer focuses exclusively on investment analysis, particularly retirement investing and stock analysis. His articles cover various investment strategies and provide insights into specific stocks and exchange-traded funds (ETFs). Therefore, Cory would likely be interested in receiving pitches from finance professionals who can offer expert commentary or unique perspectives on retirement investing, ETFs, stock analysis, or different investment strategies.
Given his focus on providing actionable advice to investors through his articles, he may also be open to pitches that present case studies of successful investment strategies or alternative viewpoints supported by data-driven analyses.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Dollar Tree no longer demonstrates the ability to outpace inflation, a key trait for high-quality, long-term investments. Click for my DLTR stock update.
Micron Technology delivered strong returns using a disciplined, deep cyclical investment strategy. Click here to find out why I rate MU stock a Sell.
Summary Brown-Forman remains overvalued, with medium- and long-term returns likely to underperform cash equivalents and short-term Treasuries.
By: Cory Cramer
Dollar General stock is overvalued after strong gains. Read why now may be the time to take profits and what to expect for future returns.
After a strong rally, I am reassessing Medpace's valuation versus the S&P 500, focusing on payback period and sustainable growth assumptions. Read the full analysis here.
Summary Medpace (MEDP) has delivered superior returns, more than doubling the S&P 500 since its buy trigger below $279 in April 2025.
By: Cory Cramer
Summary I analyzed 42 S&P 500 stocks rated 'Sell' from April 2019 to February 2020 using my Full-Cycle Analysis valuation method.
By: Cory Cramer
Thinking about long-term stock performance and portfolio strategy evolution? Read more on how one approach delivered for an investor.
By: Cory Cramer
S&P 500’s 27% earnings growth may be illusory, driven by inflation, AI spending loops, and accounting effects. Read more macro analysis here.
